Loading...
Antiangiogenic agents are the cornerstone of palliative chemotherapy for advanced hepatocellular cancer (HCC). Immune checkpoint inhibitors also have activity in this disease and have conditional regulatory approval to treat patients with refractory HCC, but randomized trials of these agents have failed to indicate superior survival compared with standard therapies or best supportive care.
Investigators now report results of an industry-sponsored, international, open-label, randomized, phase III trial (IMbrave150) in which 336 patients with advanced HCC who had not received prior palliative systemic therapy were assigned 2:1 to receive combination therapy with the antiangiogenic agent bevacizumab plus the immune checkpoint inhibitor atezoliz…